LIVERPOOL, United Kingdom & RESEARCH TRIANGLE PARK, N.C., & MORRISTOWN, N.J.--(BUSINESS WIRE)--Eden Biodesign, a globally-integrated provider of biopharmaceutical services and Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the completion of the acquisition of Eden Biopharm Group Limited by Watson for approximately $15 million. As a result of the acquisition of the Arrow Group in December 2009, Watson had previously acquired approximately 36 percent of Eden. Eden, which will be part of Watson’s Global Brands Division, will maintain its established contract services model, while providing Watson with proven biopharmaceutical development and manufacturing capabilities.
